JNJ

J&J, UPenn announce launch of Philly JLabs healthcare incubator
J&J, UPenn announce launch of Philly JLabs healthcare incubator
Mass Device
JNJ
innovation
U Penn
Philadelphia
Flag link:
[video+transcript]These 2 Healthcare Giants Had Diverging Short-Term Moves, but Have Parallel Long-Term Stories
[video+transcript]These 2 Healthcare Giants Had Diverging Short-Term Moves, but Have Parallel Long-Term Stories
Motley Fool
earnings
Unitedhealth Group
JNJ
Flag link:
Where does J&J's new drug fit in the crowded HIV market?
Where does J&J's new drug fit in the crowded HIV market?
Biopharma Dive
JNJ
Janssen
FDA
HIV
Symtuza
Flag link:
Johnson & Johnson beats revenue, profit projections for 2Q
Johnson & Johnson beats revenue, profit projections for 2Q
Yahoo/AP
JNJ
earnings
Flag link:
J&J declares a historic success as Invokana comes through in PhIII chronic kidney disease trial
J&J declares a historic success as Invokana comes through in PhIII chronic kidney disease trial
Endpoints
JNJ
Invokana
chronic kidney disease
Flag link:
J&J taps German Merck to market Invokana in China
J&J taps German Merck to market Invokana in China
Biopharma Dive
JNJ
Xian-Janssen
Merck KGaA
Invokana
China
Flag link:
Johnson & Johnson Hit by $4.7 Billion Jury Verdict in Ovarian Cancer Case
Johnson & Johnson Hit by $4.7 Billion Jury Verdict in Ovarian Cancer Case
TheStreet.com
JNJ
ovarian cancer
Flag link:
Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more
Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more
Endpoints
Genmab
JNJ
Europe
cancer immunotherapy
Immatics
Flag link:
J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What's Up?
J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What's Up?
Yahoo/Zacks.com
JNJ
earnings
Flag link:
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Fierce Pharma
JNJ
Tremfya
MorphoSys
Janssen
Crohn's Disease
clinical trials
Flag link:
More than $100 Billion Spent on M&A in the First 6 Months of 2018
More than $100 Billion Spent on M&A in the First 6 Months of 2018
BioSpace
M&A
biotech
Celgene
Sanofi
Impact Biomedicines
Bioverativ
GSK
Takeda
Shire
JNJ
Flag link:
Trump invites pharma heads to private dinner during London visit, a trip that’s inspiring tens of thousands to protest
Trump invites pharma heads to private dinner during London visit, a trip that’s inspiring tens of thousands to protest
Endpoints
Donald Trump
UK
Brexit
JNJ
GSK
Pharma CEOs
Alex Gorsky
Emma Walmsley
Flag link:
J&J scores third appeals win—this one for $55M—in talc powder litigation
J&J scores third appeals win—this one for $55M—in talc powder litigation
Fierce Pharma
JNJ
Flag link:
Amgen Announces Top-Line Data From Remicade Biosimilar Study
Amgen Announces Top-Line Data From Remicade Biosimilar Study
Yahoo/Zacks.com
Amgen
ABP 710
JNJ
Merck
Remicade
biosimilars
rheumatoid arthritis
Flag link:
Dare to 'Dreem': J&J Invests in Sleep-Focused Medtech Startup
Dare to 'Dreem': J&J Invests in Sleep-Focused Medtech Startup
Medical Devices and Diagnostics Industry
Dreem
JNJ
devices
neurotech
Flag link:
ADA: J&J's Invokana and rivals cut heart failure hospitalizations without increasing amputation risk
ADA: J&J's Invokana and rivals cut heart failure hospitalizations without increasing amputation risk
Fierce Pharma
JNJ
Invokana
diabetes
heart failure
Flag link:
J&J's Drug Unit Chief Expands Portfolio in Executive Shakeup
J&J's Drug Unit Chief Expands Portfolio in Executive Shakeup
Yahoo/Bloomberg
JNJ
Joaquin Duato
reorganization
Flag link:
Johnson & Johnson hits the Big Apple with latest JLabs site
Johnson & Johnson hits the Big Apple with latest JLabs site
Mass Device
JNJ
New York
NYC
incubators
innovation
Flag link:
New York Judge's Ruling Could Be Painful For Opioid-Makers Sued Over Addiction Crisis
New York Judge's Ruling Could Be Painful For Opioid-Makers Sued Over Addiction Crisis
Forbes
New York
opioids
opioid crisis
Purdue Pharma
JNJ
Flag link:
After split from Actelion, Idorsia CEO plans to raise more cash in 2019
After split from Actelion, Idorsia CEO plans to raise more cash in 2019
Yahoo/Reuters
Indorsia
Actelion
JNJ
insomnia
Flag link:

Pages